Aveo stock rebounds a bit after big plunge

The FDA’s decision could delay the drug’s approval.
The FDA’s decision could delay the drug’s approval.Reuters/File 2012

This is a summary. To read the whole story subscribe to

It was hardly a rebound, but Aveo Pharmaceuticals Inc. gained some ground Wednesday, a day after its stock plummeted 31.3 percent as the Food and Drug Administration said it may require another clinical trial of the Cambridge company’s drug for advanced renal cell carcinoma, tivozanib. The FDA had been scheduled to decide by July 28 whether to approve the drug but raised questions about whether it improves survival rates more than a drug that’s already available.

Full story for subscribers.

Get the full story with unlimited access to

Just 99 cents for four weeks.